T&R Biofab티앤알바이오팹
246710 · KOSDAQ · ₩246710 · 티앤알바이오팹
₩1,877▼ ₩29 (1.52%)End-of-day · Oct 29, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩27B | ₩4.9B | ₩5.2B | ₩5.8B | ₩3.2B |
| Cost of sales | ₩20B | ₩2.7B | ₩4.1B | ₩4.2B | ₩3.4B |
| Gross profit | ₩6.9B | ₩2.1B | ₩1.1B | ₩1.5B | −₩212M |
| Operating income | −₩9.1B | −₩13B | −₩13B | −₩13B | −₩10B |
| Net income | −₩32B | −₩7.7B | −₩13B | −₩10B | −₩11B |
| Net income to shareholders | −₩32B | −₩7.7B | −₩13B | −₩10B | −₩11B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩93B | ₩98B | ₩100B | ₩76B | ₩82B |
| Current assets | ₩18B | ₩26B | ₩58B | ₩47B | ₩64B |
| Cash and equivalents | ₩7.8B | ₩17B | ₩20B | ₩35B | ₩24B |
| Total liabilities | ₩67B | ₩74B | ₩69B | ₩37B | ₩41B |
| Current liabilities | ₩14B | ₩41B | ₩51B | ₩29B | ₩1.7B |
| Borrowings | ₩29B | ₩43B | ₩44B | ₩20B | ₩827M |
| Total equity | ₩26B | ₩24B | ₩31B | ₩39B | ₩42B |
| Shareholders' equity | ₩26B | ₩24B | ₩31B | ₩39B | ₩42B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | −₩7.5B | −₩12B | −₩7B | −₩5.9B | −₩7.6B |
| Free cash flow | −₩7.5B | −₩12B | −₩7B | −₩5.9B | −₩7.6B |
Consolidated where available. Amounts in won.
Also known as: T&R Biofab / 티앤알바이오팹 / 246710 / KRX:246710
Source: KRX statistical information